Researchers looked at the 250 drugs with the greatest Medicare Part D spending in 2016, and found 46 percent of them did not have a cost-effectiveness analysis. Those 115 drugs with absent cost-effectiveness analyses represent 33 percent of all Medicare Part D spending.
For the 135 drugs with available cost-effectiveness analyses, many of the studies failed to meet minimum quality standards, according to the report.
Ninety-one of the drugs included in the study had a generic equivalent, and 159 had some exclusivity.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
